1National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Am J Kidney Dis,2002,39(2 Suppl 1):S1 -266.
2Kidney Disease Outcomes Quality Initiative (K/DOQI).K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease.Am J Kidney Dis,2004,43 (5 Suppl1):S1 -290.
3De Nicola L,Minutolo R,Bellizzi V,et al.Investigators of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD)Study Group.Achievement of target blood pressure levels in chronic kidney disease:a salty question ? Am J Kidney Dis,2004,43 (5):782-795.
4Vasavada N,Agarwal R.Role of excess volume in the pathophysiology of hypertension in chronic kidney disease.Kidney Int,2003,64(5):1772-1779.
5Kooman JP,van der Sande FM,Leunissen KM.Role of sodium and volume in the pathogenesis of hypertension in dialysis patients.Reflections on pathophysiological mechanisms.Blood Purif,2004,22(1):55 -59.
6Humke U,Ziegler M.Renovascular arterial hypertension:current aspects of physiopathology,diagnosis and treatment.Ann Urol,1997,31 (2):64-69.
7Mailloux LU.Hypertension in chronic renal failure and ESRD:prevalence,pathophysiology,and outcomes.Semin Nephrol,2001,21 (2):146-156.
8Freel EM,Connell JM.Mechanisms of hypertension:the expanding role of aldosterone.J Am Soc Nephrol,2004,15 (8):1993-2001.
9Sato A,Hayashi K,Saruta T.Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.Am J Hypertens,2005,18 (1):44-49.
5Zoccali C,Ma llamaci F,Ttripepi G.Novel cardiovascular rick foctors in end-stage ronal disease[J].J Am soc Nephrol,2004,15(suppl 1):S77.
6Shimada K, Kitazato KT, Kinouchi T, et al. Activarion of estrogenreceptor-a and of angiotensin-converting enzyme 2 suppresses ischemic brain damage in oophorectomized rats. Hypertension, 2011 (57): 1161- 1166.
7Mirza FS, Ong P, Collins P, et al. Effects of estradiol and the angiotensin Ⅱ receptor blocker irbesartan on vascular function in postmenopausal women. Menopause, 2008(15):44-50.
8Villa P, Suriano R, Ricciardi I , et al. Low-dose estrogen and drospirenone combination : Effects on glycoinsulinenfic metabolism and other cardiovascular risk factors in healthy postm enopausal women. Fertil Steril, 2011 (95): 158-163.
9Gambacciani M , Rosano G , Cappagli B, et al. Clinical and metabolic effects of drospirenone-estradiol in menopausal women : A prospective study. Climacteric, 2011(14):18-24.
